Scilex Holding Co
Company Profile
Business description
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Contact
960 San Antonio Road
Palo AltoCA94303
USAT: +1 650 516-4310
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
30
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,032.00 | 53.10 | -0.58% |
| CAC 40 | 8,112.02 | 8.44 | 0.10% |
| DAX 40 | 24,351.12 | 11.06 | 0.05% |
| Dow JONES (US) | 48,461.93 | 249.04 | -0.51% |
| FTSE 100 | 9,866.53 | 4.15 | -0.04% |
| HKSE | 25,635.23 | 183.70 | -0.71% |
| NASDAQ | 23,474.35 | 118.75 | -0.50% |
| Nikkei 225 | 50,526.92 | 223.47 | -0.44% |
| NZX 50 Index | 13,530.72 | 4.73 | 0.03% |
| S&P 500 | 6,905.74 | 24.20 | -0.35% |
| S&P/ASX 200 | 8,725.70 | 51.00 | -0.58% |
| SSE Composite Index | 3,965.28 | 1.60 | 0.04% |